Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

69.53 

0.94 1.4%

as of May 14 '21

52 Week Range:

43.11 72.61


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 10.99
10.70
12.31
12.66
13.08
13.87
14.22
14.77
15.59
16.81
17.51
growth rate -2.6% 15.1% 2.8% 3.3% 6.0% 2.5% 3.9% 5.6% 7.8% 4.2%
Earnings BIT 25.91
-100.06
11.26
9.77
72.30
111.01
98.43
120.27
102.35
121.06
50.19
growth rate -100.0% 100.0% -13.2% 640.0% 53.5% -11.3% 22.2% -14.9% 18.3% -58.5%
Avg.PE 14.90
-14.00
217.39
192.31
-56.71
32.04
91.91
41.18
120.80
81.61
44.53
growth rate -100.0% 100.0% -11.5% -100.0% 100.0% 186.9% -55.2% 193.4% -32.4% -45.4%
ROA 10.76
-7.25
0.27
0.67
-1.33
5.04
2.60
5.17
0.75
3.63
-1.62
growth rate -100.0% 100.0% 148.2% -100.0% 100.0% -48.4% 98.9% -85.5% 384.0% -100.0%
ROE 21.43
-15.05
0.61
1.39
-2.71
9.93
5.35
11.14
1.53
7.46
-4.05
growth rate -100.0% 100.0% 127.9% -100.0% 100.0% -46.1% 108.2% -86.3% 387.6% -100.0%
ROIC 13.80
-7.44
2.16
2.97
0.08
7.99
4.96
8.89
2.82
6.20
0.82
growth rate -100.0% 100.0% 37.5% -97.3% 9,887.5% -37.9% 79.2% -68.3% 119.9% -86.8%
Cur. Ratio 3.41
2.85
3.13
4.58
3.28
7.06
2.37
3.48
3.44
3.69
1.87
growth rate -16.4% 9.8% 46.3% -28.4% 115.2% -66.4% 46.8% -1.2% 7.3% -49.3%
Quick Ratio 2.35
1.92
2.13
3.00
2.24
4.87
1.34
1.69
1.75
2.05
1.48
growth rate -18.3% 10.9% 40.9% -25.3% 117.4% -72.5% 26.1% 3.6% 17.1% -27.8%
Leverage 1.85
2.27
2.16
1.98
2.10
1.86
2.26
2.06
2.05
2.06
2.93
growth rate 22.7% -4.9% -8.3% 6.1% -11.4% 21.5% -8.9% -0.5% 0.5% 42.2%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 76.60
142.29
117.19
141.85
118.96
127.60
171.60
200.22
196.49
211.53
207.07
growth rate 85.8% -17.6% 21.0% -16.1% 7.3% 34.5% 16.7% -1.9% 7.7% -2.1%
Acct.Payable 73.96
89.96
117.15
13.65
6.79
9.12
4.37
8.80
11.83
17.39
growth rate 21.6% 30.2% -88.4% -50.2% 34.3% -52.1% 101.5% 34.4% 47.0%
Cur.Assets 371.80
591.84
513.75
536.01
657.96
702.83
575.44
560.06
618.21
764.34
1,562.18
growth rate 59.2% -13.2% 4.3% 22.8% 6.8% -18.1% -2.7% 10.4% 23.6% 104.4%
Total Assets 802.00
1,123.56
1,163.79
1,179.57
1,341.57
1,302.67
1,570.80
1,640.14
1,707.86
1,885.29
2,693.08
growth rate 40.1% 3.6% 1.4% 13.7% -2.9% 20.6% 4.4% 4.1% 10.4% 42.9%
Cash 92.60
163.49
123.30
102.83
142.39
192.34
153.64
72.80
117.84
213.03
856.87
growth rate 76.6% -24.6% -16.6% 38.5% 35.1% -20.1% -52.6% 61.9% 80.8% 302.2%
Inventory 107.60
119.31
126.36
136.94
154.64
168.14
208.25
247.14
273.24
312.42
300.62
growth rate 10.9% 5.9% 8.4% 12.9% 8.7% 23.9% 18.7% 10.6% 14.3% -3.8%
Cur.Liabilities 109.00
207.38
164.28
117.15
214.10
99.62
242.50
161.40
179.46
206.92
836.36
growth rate 90.3% -20.8% -28.7% 82.8% -53.5% 143.4% -33.4% 11.2% 15.3% 304.2%
Liabilities 367.70
629.52
626.21
583.78
693.21
583.82
870.28
840.72
873.33
970.08
1,774.16
growth rate 71.2% -0.5% -6.8% 18.8% -15.8% 49.1% -3.4% 3.9% 11.1% 82.9%
LT Debt 230.00
394.02
332.40
346.06
360.75
372.92
564.41
582.92
602.53
623.30
766.23
growth rate 71.3% -15.6% 4.1% 4.2% 3.4% 51.4% 3.3% 3.4% 3.5% 22.9%
Equity 434.40
494.05
537.58
595.79
640.05
711.53
694.94
795.57
834.53
915.21
918.92
growth rate 13.7% 8.8% 10.8% 7.4% 11.2% -2.3% 14.5% 4.9% 9.7% 0.4%
Common Shares 46.00
40.00
44.00
47.00
47.00
52.00
54.00
55.00
52.00
53.00
51.00
growth rate -13.0% 10.0% 6.8% 0.0% 10.6% 3.9% 1.9% -5.5% 1.9% -3.8%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 45.80
53.37
41.19
47.60
58.42
75.77
88.37
110.22
101.92
122.88
105.73
growth rate 16.5% -22.8% 15.6% 22.8% 29.7% 16.6% 24.7% -7.5% 20.6% -14.0%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA 65.80
62.97
130.08
97.44
115.55
88.73
158.09
176.97
219.18
235.29
185.91
growth rate -4.3% 106.6% -25.1% 18.6% -23.2% 78.2% 12.0% 23.9% 7.4% -21.0%
FCF per Share 0.44
0.59
2.01
1.25
1.46
-0.67
0.70
1.16
2.13
1.97
1.49
growth rate 34.1% 240.7% -37.8% 16.8% -100.0% 100.0% 65.7% 83.6% -7.5% -24.4%
Sale Purchase of Stock 54.75
4.88
8.42
23.35
12.11
9.49
9.99
growth rate -91.1% 72.4% 177.3% -48.2% -21.6% 5.3%
FCF 20.00
10.00
89.00
50.00
57.00
-19.00
62.00
66.00
110.00
105.00
76.00
growth rate -50.0% 790.0% -43.8% 14.0% -100.0% 100.0% 6.5% 66.7% -4.6% -27.6%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 478.20
540.51
620.26
685.17
762.42
811.11
962.13
1,026.69
1,101.71
1,168.07
1,050.58
growth rate 13.0% 14.8% 10.5% 11.3% 6.4% 18.6% 6.7% 7.3% 6.0% -10.1%
Op.Income 32.10
-69.85
3.14
7.90
72.30
111.01
98.43
120.27
102.35
121.06
50.19
growth rate -100.0% 100.0% 151.3% 815.0% 53.5% -11.3% 22.2% -14.9% 18.3% -58.5%
IBT 25.90
-100.06
11.26
9.77
-11.21
112.02
64.78
72.36
8.72
80.52
-47.55
growth rate -100.0% 100.0% -13.2% -100.0% 100.0% -42.2% 11.7% -88.0% 823.0% -100.0%
Net Income 78.30
-69.85
3.14
7.90
-16.72
66.29
37.19
81.60
12.48
65.23
-37.15
growth rate -100.0% 100.0% 151.3% -100.0% 100.0% -43.9% 119.4% -84.7% 422.8% -100.0%
EPS 1.85
-1.73
0.07
0.17
-0.36
1.26
0.69
1.48
0.24
1.23
-0.72
growth rate -100.0% 100.0% 142.9% -100.0% 100.0% -45.2% 114.5% -83.8% 412.5% -100.0%
Gross Profit 393.10
428.40
466.85
504.69
580.06
616.63
722.03
758.24
790.56
855.71
728.95
growth rate 9.0% 9.0% 8.1% 14.9% 6.3% 17.1% 5.0% 4.3% 8.2% -14.8%
R&D 40.90
38.41
35.30
32.21
37.49
35.83
48.00
50.43
61.70
72.38
79.84
growth rate -6.1% -8.1% -8.8% 16.4% -4.4% 34.0% 5.1% 22.4% 17.3% 10.3%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT 26.88
-35.42
30.16
28.57
growth rate -100.0% 100.0% -5.3%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 186.83
182.14
205.26
207.07
205.03
growth rate -2.5% 12.7% 0.9% -1.0%
Acct.Payable 90.08
102.59
111.08
17.39
growth rate 13.9% 8.3% -84.4%
Cur.Assets 1,058.40
1,457.52
1,521.94
1,562.18
781.56
growth rate 37.7% 4.4% 2.6% -50.0%
Total Assets 2,220.52
2,649.97
2,656.57
2,693.08
2,164.79
growth rate 19.3% 0.3% 1.4% -19.6%
Cash 511.98
796.77
774.54
856.87
233.86
growth rate 55.6% -2.8% 10.6% -72.7%
Inventory 324.68
312.21
305.63
300.62
315.75
growth rate -3.8% -2.1% -1.6% 5.0%
Cur.Liabilities 782.14
793.43
820.63
836.36
224.88
growth rate 1.4% 3.4% 1.9% -73.1%
Liabilities 1,334.32
1,755.08
1,757.19
1,774.16
growth rate 31.5% 0.1% 1.0%
LT Debt 361.63
746.72
756.17
766.23
879.47
growth rate 106.5% 1.3% 1.3% 14.8%
Equity 886.20
894.89
899.38
918.92
835.39
growth rate 1.0% 0.5% 2.2% -9.1%
Common Shares 0.06
0.06
0.06
0.06
0.06
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 28.12
23.95
25.79
27.87
growth rate -14.8% 7.7% 8.1%
Cash Dividends
growth rate
Cash From OA 5.23
27.88
80.09
72.71
31.64
growth rate 433.6% 187.3% -9.2% -56.5%
Sale Purchase of Stock
growth rate
FCF -22.89
3.93
54.30
44.84
growth rate 100.0% 1,280.6% -17.4%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 259.88
203.61
295.28
291.81
271.25
growth rate -21.7% 45.0% -1.2% -7.1%
Op.Income 26.88
-35.42
30.16
28.57
growth rate -100.0% 100.0% -5.3%
IBT 10.13
-65.19
6.45
1.06
-8.13
growth rate -100.0% 100.0% -83.5% -100.0%
Net Income 5.30
-50.02
5.87
1.69
-7.51
growth rate -100.0% 100.0% -71.2% -100.0%
EPS
growth rate
Gross Profit 188.02
123.11
210.65
207.18
199.44
growth rate -34.5% 71.1% -1.7% -3.7%
R&D 18.26
19.41
20.40
21.77
22.22
growth rate 6.3% 5.1% 6.7% 2.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (9.46)

YOY Growth Grade:

E (31.02)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 44.53 60.46 25.47
EPS / Growth 19.0% 1.15 20.3%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 5.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 5.7% 15.0% 15.0%
Future PE 11.44 33.33 33.33
Future EPS 2.01 4.65 4.65
Value Price
MOS %
5.67
-91.8%
38.29
-44.9%
38.29
-44.9%
MOS Price 2.84 19.15 19.15
IRT 26.10 15.62 15.62

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.